Contribution of non-steroidal anti-inflammatory drugs to breast cancer treatment: in vitro and in vivo studies

• Author(s): Ferreira, Tiago ; Faustino-Rocha, Ana I ; Gaspar, VM ; Medeiros, Rui ; Mano, JF ; Oliveira, Paula A.
• Date: 2024
• Persistent ID: http://hdl.handle.net/10174/37294
• Origin: Repositório Científico da Universidade de Évora
• Document Type: Journal article
• Language: English

Description

Chronic inflammation plays a crucial role in carcinogenesis. High levels of serum prostaglandin E2 and tissue overexpression of cyclooxygenase-2 (COX-2) have been described in breast, urinary, colorectal, prostate, and lung cancers as being involved in tumor initiation, promotion, progression, angiogenesis, and immunosuppression. Non-steroidal anti-inflammatory drugs (NSAIDs) are prescribed for several medical conditions to not only decrease pain and fever but also reduce inflammation by inhibiting COX and its product synthesis. To date, significant efforts have been made to better understand and clarify the interplay between cancer development, inflammation, and NSAIDs with a view toward addressing their potential for cancer management. This review provides readers with an overview of the potential use of NSAIDs and selective COX-2 inhibitors for breast cancer treatment, highlighting pre-clinical in vitro and in vivo studies employed to evaluate the efficacy of NSAIDs and their use in combination with other antineoplastic drugs.